3S Pharmaceutical Group China

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Zhao Peng
Senior BD Manager 

Adragos Pharma Germany

Private equity firm
Company Size (Fulltime employees)
Please specify your partnering goal
Both raising further funds and driving deal pipeline
Headquartner in China
Mr. Andreas Raabe
Partner 
Functionality

Aeola Health Solutions United States

An investment group transforming

the world of healthcare one sector at a time.

We consolidate CROs and medical labs.
Company Size (Fulltime employees)
Please specify your partnering goal
Find potential investors and strategic partners. Our strategy allows investors to triple their investment.
Headquartner in China
Mr. Michael Ezem
Aeola Health Solutions 
Functionality

AnHeart Therapeutics China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua  Zheng
Dr Lihua Zheng
LinkedIn logo CBO & co-Founder 
Functionality
Dr. Weiqing Wang
Associate Director of BD 
Functionality
Dr. Akira Liu
Director of BD 
Functionality

Biosion Inc., China

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.
Company Size (Fulltime employees)
Year of foundation
2013
Please specify your partnering goal
Seeking partners in big pharma or established biotech companies to co-develop or license assets from Biosion's pipeline or to explore new collaborations for innovative antibody discovery by using our proprietary H³ antibody discovery platform and SynAb™ technology. We are also seeking additional investment to support advancement of our innovative antibody pipeline move into the clinic.
Headquartner in China
Assets Information 1
BSI-045B|TSLP: High affinity superior humanized antibody for the treatment of asthma and atopic dermatitis (Ex-China global rights)|Severe Asthma|Pending
Assets Information 2
BSI-03802|CD40: Humanized antibody molecule with superior agonist activity (Ex-China global rights)|solid cancer|Pending
Assets Information 3
BSI-001|HER2: hu5G9, best-in-class efficacy partner of trastuzumab and for next generation HER2 ADC development|HER2+ cancer|PCT
Biotech/Pharma Asset Stage
Dr. Mingjiu Chen
CEO 
Functionality

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Dr. Chirag Jain
Analyst 
Functionality

InnoCare China

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

Company Size (Fulltime employees)
Year of foundation
5
Headquartner in China
Biotech/Pharma Category
Jasmine Cui
CEO 
Chunhua Lu
Head of Communication 

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Company Size (Fulltime employees)
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality